

EUROPEAN CURRICULUM VITAE FORMAT



PERSONAL INFORMATION

Name
Profession
E-mail
Nationality
Date of birth

DADDUZIO VINCENZO

MEDICAL ONCOLOGIST
vincenzo.dadduzio@iov.veneto.it
Italian
24TH OCTOBER, 1984

WORK EXPERIENCE

- Dates (from – to)
- Name and address of employer
 - Type of business or sector
 - Occupation or position held
- Main activities and responsibilities

MARCH 2016 - PRESENT

Dr.Vittorina Zagonel – Oncologia Medica 1 – Istituto Oncologico Veneto IRCCS, Padua
Medical Oncology
Medical Oncologist
Reference Physician for gastrointestinal malignancies for clinical and research activity,
Conduction of phase I-III clinical trials according to GCP, Multidisciplinary team member

- Dates (from – to)
- Name and address of employer
 - Type of business or sector
 - Occupation or position held
- Main activities and responsibilities

OCTOBER 2015 – PRESENT

Prof.Carlo Barone – Oncologia Medica – Fondazione Policlinico “A.Gemelli” / Università Cattolica del Sacro Cuore, Rome
Medical Oncology
PhD fellow in Oncology
Project of Research: prognostic and predictive value of genes involved in EGFR pathway for patients affected by metastatic colorectal cancer

- Dates (from – to)
- Name and address of employer
 - Type of business or sector
 - Occupation or position held
- Main activities and responsibilities

MAY 2015 – FEBRUARY 2016

Prof.Carlo Barone – Oncologia Medica – Fondazione Policlinico “A.Gemelli” / Università Cattolica del Sacro Cuore, Rome
Medical Oncology
Medical Oncologist
Fellow Physician in clinical practice and clinical research. Conduction of phase I-III clinical trials according to GCP. Multidisciplinary team member

EDUCATION AND TRAINING

- Dates (from – to)
- Name and type of organisation providing education and training
- Principal subjects/occupational skills covered
- Title of qualification awarded
- Level in national classification

MAY 2010 – MAY 2015

Università Cattolica del Sacro Cuore, Policlinico Universitario “Agostino Gemelli” Rome, Italy.
Director: Prof. Carlo Barone. Fellowship Training Program in Medical Oncology.
Inpatient and ambulatory care of oncologic patients. Conduction of phase I-II-III clinical trials in medical oncology field as sub-investigator. Member of multidisciplinary team for patients treatment.
Medical Oncology Specialist
50/50 cum laude. Thesis: KRAS exon 2 mutations in advanced colorectal cancer are not bad prognostic indicators in real life clinical practice. A mono-institutional retrospective study.

- Dates (from – to)
- Name and type of organisation providing education and training
- Title of qualification awarded

- Dates (from – to)
- Name and type of organisation providing education and training
- Title of qualification awarded
- Level in national classification

OCTOBER 2012 - NOVEMBER 2013

Italian Society of Ultrasonology (SIUMB)

National Certificate in Clinical Ultrasonography

OCTOBER 2003 – OCTOBER 2009

Università Cattolica del Sacro Cuore, Policlinico Universitario "Agostino Gemelli" Rome, Italy.
Director: Prof. Carlo Barone. Medicine and Surgery school.

Medical Doctor

110/110 cum laude. Thesis: Possible role of anti-CTLA4 monoclonal antibodies in Oncology: a phase I study in pancreatic cancer.

PERSONAL SKILLS AND COMPETENCES

MOTHER TONGUE

ITALIAN

OTHER LANGUAGES

ENGLISH

- Reading skills
- Writing skills
- Verbal skills

EXCELLENT

EXCELLENT

EXCELLENT

FRENCH

- Reading skills
- Writing skills
- Verbal skills

BASIC

BASIC

BASIC

TECHNICAL SKILLS AND COMPETENCES

Good expertise in Windows and Mac OS operating systems.

Good expertise in MS Office softwares: Word, Excel, PowerPoint.

Good expertise in Data Analysis softwares: SPSS, MedCalc

MEMBERSHIP / ASSOCIATION

AIOM member since 2012

ESMO member since 2012

ADDITIONAL INFORMATIONS

SCIENTIFIC ACTIVITY

Author/Co-author of peer-reviewed scientific papers and meeting abstracts in medical oncology field, invited speaker for scientific meetings.

SCIENTIFIC PUBLICATIONS

- KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study.

Dadduzio V, Basso M, Rossi S, Cenci T, Capodimonti S, Strippoli A, Orlandi A, Cerchiaro E, Schinzari G, Cassano A, Martini M, Barone C.

Mol Diagn Ther. 2016 Feb;20(1):65-74

- Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases: A Retrospective, STROBE-Compliant, Single-Center Study Comparing Chemotherapy Alone and Combination Chemotherapy With Cetuximab or Bevacizumab.

Basso M, **Dadduzio V**, Ardito F, Lombardi P, Strippoli A, Vellone M, Orlandi A, Rossi S, Cerchiaro E, Cassano A, Giuliante F, Barone C.

Medicine (Baltimore). 2016 May;95(20):e3722

- Are TKIs favourable for the elderly with non-small-cell lung cancer?
Rossi S, D'Argento E, Schinzari G, Dadduzio V, Di Noia V, Cassano A, Barone C.
Oncotarget. 2016 Jul 26;7(30):46871-46877. doi: 10.18632/oncotarget.9389.
- Maintenance hormonal and chemotherapy treatment in metastatic breast cancer: a systematic review.
Rossi S, Schinzari G, Basso M, Strippoli A, Dadduzio V, D'Argento E, Cassano A, Barone C.
Future Oncol. 2016 May;12(10):1299-307
- Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis.
Rossi S, D'Argento E, Basso M, Strippoli A, Dadduzio V, Cerchiaro E, Martini M, Cassano A, Barone C.
Mol Diagn Ther. 2016 Feb;20(1):55-63
- Hormon receptor status and Her2 expression in primary breast cancer in comparison to synchronous axillary metastases or recurrent metastatic disease.
Rossi S, Basso M, Strippoli A, Dadduzio V, Cerchiaro E, Barile R, D'Argento E, Cassano A, Schinzari G, Barone C.
Clin Breast Cancer. 2015 Oct;15(5):307-12

MEETING ABSTRACTS

- K-RAS exon 2 mutations in advanced colorectal cancer: are they really so bad prognostic indicators? A phase 2 mono-institutional retrospective study.
Dadduzio V, Basso M, Rossi S, Cenci T, Cerchiaro E, Capodimonti S, Strippoli A, Larocca M, Lombardi P, Bensi M, Cassano A, Martini M, Barone C.
ESMO 17th World Congress on Gastrointestinal Cancer - Ann Oncol 26 (Supplement 4, 2015 – P-237).
- Combined versus sequential adjuvant therapy of biliary tract cancer: what is the best option?
Cassano A, Mattiucci GC, Cerchiaro E, Di Noia VP, De Filippo L, Autorino R, Dadduzio V, Rossi S, Ardito F, Giuliante F, Basso M, Valentini V.
ESMO 17th World Congress on Gastrointestinal Cancer - Ann Oncol 26 (Supplement 4, 2015 – P-141).
- K-RAS codon 13 mutation in advanced colorectal cancer: A single-center retrospective study investigating prognostic outcomes and treatment strategies.
Dadduzio V, Basso M, Bensi M, Cona S, Cerchiaro E, Strippoli A, Campitiello M, Rossi S, Orlandi A, Plastino F, Calegari MA, Semenova D, Cassano A, Barone C.
2015 ASCO Gastrointestinal Cancer Symposium - J Clin Oncol 33, 2015 (suppl 3; abstr 633)
- Gastrointestinal stromal tumors (GIST) and second malignancies: a novel "sentinel tumor"?
Rodriquenz MG, Ricci R, Iezzi M, Martini M, Basso M, Dadduzio V, Larocca LM, Barone C, Cassano A.
ESMO 2014 Congress - Ann Oncol (2014) 25(suppl 4):iv501 (ref 1431P)
- Conversion chemotherapy for technically unresectable colorectal liver metastases: a retrospective, single-center study comparing chemotherapy alone or in combination with cetuximab or bevacizumab
Dadduzio V, Basso M, Ardito F, Mannavola F, Rodriquenz M G, Vellone M, Marsico V, Cerchiaro E, Di Nardo P, Cassano A, Giuliante F, Barone C.
ESMO 16th World Congress on Gastrointestinal Cancer - Ann Oncol (2014) 25(suppl 2):ii92 (ref.P0249)
- Folfirinox in metastatic pancreatic adenocarcinoma: preliminary results of a single center phase 2 study
Strippoli A, Inno A, Quirino M, Schinzari G, Dadduzio V, Rodriquenz M, Amoruso A, Campitiello M, Marsico V, Pozzo C, Barone C.
XIV Congresso Nazionale AIOM – Oct 2012, Roma (ref.A18).
- Cetuximab containing regimen as induction therapy in head and neck cancer (SCCHN): our experience
Campitiello M, Plastino F, Cassano A, Rodriquenz M G, Cerchiaro E, Dadduzio V, Marsico V, Bussu F, Paludetti G, Almadori G, Barone C.
XIV Congresso Nazionale AIOM – Oct 2012, Roma (ref.D33)

- ERCC1, KRAS mutation, redox status, and oxaliplatin sensitivity in colorectal cancer: "Radical" change in an old model.

Orlandi A, Di Salvatore M, Basso M, Bagalà C, Strippoli A, Plastino F, Dadduzio E, Di Lascio S, Corsio E, Amoroso A, Rodríguez M, Cassano A, Astone A, Barone C.

ASCO 2012 Annual Meeting. J Clin Oncol 30, 2012 (suppl; abstr e14156)

INVITED SPEAKER / ORAL PRESENTATIONS

- Carcinoma renale: approccio multidisciplinare. La chirurgia immediata del tumore primitivo nell'era della "target therapy": Pro

Rome, Central Park Marriott Hotel - Dec 2015

- Sviluppi dell'immunoterapia in oncologia: esperienze a confronto nel trattamento del melanoma metastatico. Un caso di pseudo-progressione.

Rome, IFO – Nov 2014

- K-RAS codon 13 mutation in advanced colorectal cancer: a single-center retrospective study investigating prognostic outcomes and treatment strategies.

Rome, 16° Congresso Nazionale GOIM – Sep 2014